Kala Pharmaceuticals, Inc. (0JQ2.L)

USD 6.03

(-3.51%)

Inventory Summary of Kala Pharmaceuticals, Inc.

  • Kala Pharmaceuticals, Inc.'s latest annual inventory in 2023 was - USD , down -100.0% from previous year.
  • Kala Pharmaceuticals, Inc.'s latest quarterly inventory in 2024 Q2 was - USD , down 0.0% from previous quarter.
  • Kala Pharmaceuticals, Inc. reported annual inventory of 7.67 Million USD in 2022, down -11.19% from previous year.
  • Kala Pharmaceuticals, Inc. reported annual inventory of 8.63 Million USD in 2021, up 65.21% from previous year.
  • Kala Pharmaceuticals, Inc. reported quarterly inventory of - USD for 2024 Q1, down 0.0% from previous quarter.
  • Kala Pharmaceuticals, Inc. reported quarterly inventory of - USD for 2023 Q4, down 0.0% from previous quarter.

Annual Inventory Chart of Kala Pharmaceuticals, Inc. (2023 - 2015)

Historical Annual Inventory of Kala Pharmaceuticals, Inc. (2023 - 2015)

Year Inventory Inventory Growth
2023 - USD -100.0%
2022 7.67 Million USD -11.19%
2021 8.63 Million USD 65.21%
2020 5.22 Million USD 12.5%
2019 4.64 Million USD 13.5%
2018 4.09 Million USD 0.0%
2017 - USD 0.0%
2016 - USD 0.0%
2015 - USD 0.0%

Peer Inventory Comparison of Kala Pharmaceuticals, Inc.

Name Inventory Inventory Difference
Editas Medicine, Inc. - USD NaN%
Dynavax Technologies Corporation 53.29 Million USD 100.0%
Supernus Pharmaceuticals, Inc. 77.4 Million USD 100.0%
Perrigo Company plc 1.14 Billion USD 100.0%
Illumina, Inc. 587 Million USD 100.0%
Thermo Fisher Scientific Inc. 5.08 Billion USD 100.0%
Iovance Biotherapeutics, Inc. 10.37 Million USD 100.0%
Walgreens Boots Alliance, Inc. 8.32 Billion USD 100.0%
IQVIA Holdings Inc. - USD NaN%
Heron Therapeutics, Inc. 42.11 Million USD 100.0%
Regeneron Pharmaceuticals, Inc. 2.58 Billion USD 100.0%
Unity Biotechnology, Inc. - USD NaN%
Waters Corporation 516.23 Million USD 100.0%
Biogen Inc. 2.52 Billion USD 100.0%
Sangamo Therapeutics, Inc. - USD NaN%
Evolus, Inc. 10.99 Million USD 100.0%
Adicet Bio, Inc. - USD NaN%
Cara Therapeutics, Inc. 2.82 Million USD 100.0%
bluebird bio, Inc. 22.91 Million USD 100.0%
Esperion Therapeutics, Inc. 65.62 Million USD 100.0%
FibroGen, Inc. 41.56 Million USD 100.0%
Agilent Technologies, Inc. 1.03 Billion USD 100.0%
Corbus Pharmaceuticals Holdings, Inc. - USD NaN%
Homology Medicines, Inc. - USD NaN%
Geron Corporation - USD NaN%
Alnylam Pharmaceuticals, Inc. 89.14 Million USD 100.0%
Amicus Therapeutics, Inc. 59.69 Million USD 100.0%
Myriad Genetics, Inc. 20.1 Million USD 100.0%
Viking Therapeutics, Inc. - USD NaN%
Intellia Therapeutics, Inc. - USD NaN%
Zoetis Inc. 2.56 Billion USD 100.0%
Abeona Therapeutics Inc. -2.44 Million USD 100.0%
Mettler-Toledo International Inc. 385.86 Million USD 100.0%
BioMarin Pharmaceutical Inc. 1.1 Billion USD 100.0%
Vertex Pharmaceuticals Incorporated 738.8 Million USD 100.0%
Ionis Pharmaceuticals, Inc. 28.42 Million USD 100.0%
Atara Biotherapeutics, Inc. 9.7 Million USD 100.0%
Verastem, Inc. - USD NaN%
Nektar Therapeutics 16.1 Million USD 100.0%
Axsome Therapeutics, Inc. 15.13 Million USD 100.0%
Aclaris Therapeutics, Inc. - USD NaN%
Sarepta Therapeutics, Inc. 322.85 Million USD 100.0%
OPKO Health, Inc. 65.69 Million USD 100.0%
Exelixis, Inc. 17.32 Million USD 100.0%
Neurocrine Biosciences, Inc. 38.3 Million USD 100.0%
Corcept Therapeutics Incorporated 7.73 Million USD 100.0%
Anavex Life Sciences Corp. - USD NaN%
uniQure N.V. 12.02 Million USD 100.0%
Imunon, Inc. - USD NaN%
Blueprint Medicines Corporation 21.22 Million USD 100.0%
Insmed Incorporated 83.24 Million USD 100.0%
Halozyme Therapeutics, Inc. 127.6 Million USD 100.0%
Agios Pharmaceuticals, Inc. 19.07 Million USD 100.0%
TG Therapeutics, Inc. 39.82 Million USD 100.0%
Incyte Corporation 62.97 Million USD 100.0%
Emergent BioSolutions Inc. 328.9 Million USD 100.0%